Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer

Breast Cancer Clinical Trial

— VMS  

Official title:

A Randomized, Placebo-Controlled, Double-Blind, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of RCN3028 in Treatment of Drug-Induced Moderate to Severe Vasomotor Symptoms in Breast Cancer Subjects

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT06161792
• Other study ID #: YSP-RCN3028-03
• Status: Terminated
• Phase: Phase 2
• Start date: November 7, 2019
• Est. completion date: April 20, 2022

Study information

• Verified date: November 2023
• Source: Yung Shin Pharm. Ind. Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer. Prior clinical studies of tamoxifen suggested that up to 80 % of patients experienced hot flashes during therapy with tamoxifen, and 30 % defined their symptoms as severe. Despite the high efficacy of tamoxifen, the harmful side effects have been identified in previous studies as a significant reason for not persisting with the treatment in 16 - 30 % of breast cancer patients. The primary purpose of this study is to determine if RCN3028 is effective and safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot flashes per day, or 50 per week at baseline.

Description:

Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal women. Clinical evidence indicates potent antagonists of 5-HT2a are more likely to cause hypothermia. Risperidone is a potent 5-HT2a and a dopamine D2 receptor antagonist and is proposed to have effect on reduction of hot flashes through its dopaminergic and serotonergic antagonism. Breast cancer is one of the most common cancers in women, according to the cancer registration report of the Ministry of Health and Welfare (MOHW), in 2014, up to 11,976 women suffered from breast cancer, which meant 33 women suffered from breast cancer daily. Recent epidemiology further disclosed that the incidence of breast cancer was top-ranked (70.74 per 100,000) among cancers of Taiwanese women in 2014. Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer. Prior clinical studies of tamoxifen suggested that up to 80 % of patients experienced hot flashes during therapy with tamoxifen, and 30 % defined their symptoms as severe. Despite the high efficacy of tamoxifen, the harmful side effects have been identified in previous studies as a significant reason for not persisting with the treatment in 16 - 30 % of breast cancer patients. The primary purpose of this study is to determine if RCN3028 is effective and safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot flashes per day, or 50 per week at baseline. With recent advances of treatment modalities, more than 80% of women with a newly diagnosed breast cancer are expected to survive their disease for 5 years or more. One of the most common complaints was hot flashes induced by the treatment of breast cancer (i.e., tamoxifen induced hot flashes). In general, hormone replacement therapy (HRT) is the most effective treatment for VMS (hot flashes). However, HRT has been associated with increased risk of recurrence in breast cancer survivors . Moreover, there is some evidence that HRT may not be as effective in women using tamoxifen. Therefore, a new therapy for treating hot flashes in breast cancer patients without increasing the risk of cancer recurrence is needed for such patient population, for example, a non-hormonal therapy. FDA approved low-dose paroxetine capsules (Brisdelle®) as a non-hormonal therapy for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, despite the modest efficacy as compared with placebo, suicidal ideation and the drug-drug interactions (i.e., Brisdelle® and tamoxifen) . Brisdelle® itself is an antidepressant of selective serotonin reuptake inhibitors (SSRI) class. Several trials have recently demonstrated a role for SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the treatment of VMS.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: April 20, 2022
• Est. primary completion date: March 14, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Female subjects (aged 20 years or order) with confirmed diagnosis of breast cancer who have completed chemotherapy and radiotherapy, and are on a stable dose of tamoxifen or aromatase inhibitors (AIs) for at least 8 weeks at baseline and will maintain the same treatment regimen and dose throughout the study.
• Reported 7 or more moderate to severe hot flashes per day (average) or 50 moderate to severe hot flashes per week at baseline.
• Screening laboratory values for hematopoietic, hepatic, and renal functions are within

the following ranges:

• Hematopoietic : Absolute neutrophil count = 1,500/mm3?Platelet count = 100,000/mm3
• Hepatic : Glutamic Oxaloacetic Transaminase/Glutamic Pyruvic Transaminase = 3 times upper limit of normal (ULN)?Bilirubin = 1.5 times ULN
• Renal : Creatinine = 1.5 times ULN
• Having Eastern Collaborative Oncology Group (ECOG) Performance Status of = 1.
• Ability to understand and follow the instructions of the investigator, including completion of the study procedures as described in the protocol (i.e., VMS episode event log).
• Able and willing to provide written informed consent.

Exclusion Criteria:

• Subjects are pregnant or breastfeeding.
• Female subjects who have childbearing potential, but they are not willing to use effective contraceptive methods during study period and for 1 week afterward.
• Subjects who have multiple primary cancers (except for completely resected basal cell cancer, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer or any other cancer from which the patient has been recurrence-free for at least 5 years).
• Subjects who have inoperable breast cancer (Stage IIIB/IIIC/IV).
• Subjects who have the following medical history: myocardial infarction, congestive heart failure, significant ischemic or valvular heart disease, clinically active interstitial lung disease.
• Subjects who have systolic blood pressure (BP) outside the range 100 to 150 mmHg, diastolic BP outside the range 60 to 90 mmHg, and/or heart rate outside the range 50 to 100 bpm at baseline.
• Subjects who had received treatment for hypotension within 30 days prior to screening visit.
• Subjects who have uncontrolled hyperglycemia, HbA1c = 7% at baseline.
• Subjects who have clinical significant conditions such as acute myocardial infarction or stroke with 6 months of randomization.
• Subjects who have a history of Parkinson's disease.
• Subjects are taking risperidone in the 30 days prior to screening visit.
• Subjects who had participated in another clinical trial and received an investigational drug within 30 days prior to screening visit.
• Subjects having a known history of allergic reaction, hypersensitivity or clinically significant intolerance to ingredients of the study drug.
• Subjects with a current drug or alcohol abuse problem as judged by the investigator.
• Subjects who are considered unreliable as to medication compliance or adherence to scheduled appointments or for other reasons are felt to be inappropriate for inclusion in the study as determined by the investigators.
• Subjects who use Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), within 4 weeks prior to screening visit.
• Subjects who use herbal or dietary supplements, including black cohosh, soy, phytoestrogens or over the counter agents known to possibly be effective for the treatment of vasomotor symptoms within 2 weeks prior to baseline.
• Subjects who have serious, unstable, or clinically significant medical or psychological conditions, which, in the opinion of the investigator(s), would compromise the subject's participation in the study.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Hot Flashes

Intervention

Drug:
• 0.8 mg RCN3028
Oral
• Placebo
Oral

Locations

Country	Name	City	State
Taiwan	Changhua Christain Hospital	Changhua
Taiwan	Taichung Veterans General Hospital	Taichung
Taiwan	National Cheng Kung University Hospital	Tainan
Taiwan	Taipei Medical University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Yung Shin Pharm. Ind. Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in frequency of moderate to severe VMS	Mean change in frequency numbers of moderate to severe VMS(Vasomotor Symptoms) from baseline to weeks 4 and week 12. The VMS episode event log recorded the frequency of hot flashes per day, such mild, moderate, severe, nighttime awakening number.	4, 12 weeks
Primary	Mean change in severity of moderate to severe VMS	Mean change in severity score of moderate to severe VMS from baseline to weeks 4 and week 12. The severity score for VMS for each subject is calculated as the sum of 2 times the number of moderate VMS, plus 3 times the number of severe VMS, divided by the total number of moderate and severe VMS.	4, 12 weeks
Secondary	Menopause Specific Quality of Life Questionnaire	Menopause Specific Quality of Life Questionnaire will be completed at baseline, week 4, week 8 and week 12. Score on a scale Menopause Specific Quality of Life (MENQOL) questionnaire 0=not bothered at all - 6=extremely bothered. 4 domains, mean calculated for set of questions in each domain.	12 weeks
Secondary	The 50%, 75% and 100% responder rates	Subject who had a reduction in the number of moderate and severe hot flashes of at least 50%, at least 75% and 100% from baseline.	12 weeks
Secondary	The time to onset of efficacy	50% reduction in hot flashes for at least 3 consecutive days. The duration of first treatment used to first onset on efficacy will be calculated.	12 weeks
Secondary	Subject's and Physician's Global Assessment	At the end of treatment Visit (week 12) each subject will provide an overall evaluation of study treatment by completing a Subject's Global Assessment. The rating scale for the final assessment by the subject includes: much worse, worse, unchanged, improved, much improved or free of symptoms. At week 12 each investigator will be asked to rate their subject's response to therapy using the same scale.	12 weeks
Secondary	Frequencies(number and percentage) of subjects with treatment-emergent AEs (TEAEs)	Frequencies (number and percentage) of subjects with one or more treatment-emergent AEs (TEAEs) will be summarized by treatment arm, by the Medical Dictionary for Regulatory Activities (MedDRA) system with respect to System Organ Class (SOC) and preferred term.	12 weeks
Secondary	Change from baseline in weekly weighted severity score.	calculated for each week as 2 times the number of moderate hot flashes plus 3 times the number of severe hot flashes plus 3 times the number of nighttime awakenings.; The severity of VMS is defined as follows: Mild: sensation of heat without sweating; Moderate: sensation of heat with sweating, able to continue activity; Severe: sensation of heat with sweating, causing cessation of activity.; Nighttime awakenings (i.e., episodes that wake the patient from sleep) associated with hot flashes are recorded separately and are considered severe.	12 weeks
Secondary	Change from baseline in the number of mild, moderate, and severe hot flashes.	The weekly frequency will be calculated for each visit.	12 weeks
Secondary	Change from baseline in the number of nighttime awakenings because of hot flashes.	The weekly frequency will be calculated for each visit.	12 weeks